| Name | Title | Contact Details |
|---|
Blackrock Neurotech builds implantable brain technology that changes lives. Our pioneering neuroscience tools push the boundaries of research and empower innovation across more than 500+ global institutional partners, restoring function in patients suffering from neurological disease (ALS, Alzheimer`s, Parkinson`s), dysfunction (epilepsy, pain, brain trauma), and paralysis disorders.
Prodigy Health Supplier Corporation is a Austin, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ApiJect Systems, Corp. is reimagining how injectable medicines can be packaged and delivered to the world. ApiJect`s technology platform is based on a design philosophy of basic interlocking components to create simple and highly-scalable drug delivery devices. Our first product is the ApiJect Prefilled Injector, a single-dose parenteral that is manufactured in two parts: a Blow-Fill-Seal (BFS) Container aseptically filled with medicine or vaccine, and an insulin-style Needle Hub, also made by ApiJect. At the point of care, a healthcare worker attaches these two components in seconds to activate the injector. By using high-speed, high-volume Blow-Fill-Seal plastics technology, we can reliably supply millions of aseptically filled prefilled injectors per month. Simple devices like these will enable ApiJect to fulfill its mission of making injectable medicines safe and available for everyone.
TearLab Corporation develops and commercializes lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by quantitatively testing for disease markers in tears at the point-of-care. Headquartered in San Diego, CA, TearLab Corporation`s common shares trade on the NASDAQ Capital Market under the symbol `TEAR` and on the Toronto Stock Exchange under the symbol `TLB`. Dry Eye Disease (DED) is a chronic, progressive disease. Morgan Stanley’s Dry Eye Market Report (2003) estimates that 30 to 60 million Americans suffer from dry eye symptoms. Only 10 million are diagnosed with the disease. Millions more suffer worldwide. The TearLab™ Osmolarity System provides the first quantitative and objective diagnostic technology that allows doctors to effectively manage their dry eye patients. TearLab will allow practitioners to diagnosis DED patients early in the disease process allowing for early intervention. TearLab received the CE Mark for its TearLab Osmolarity System in 2008 and FDA Clearance in 2009. TearLab is currently marketed globally in more than 14 countries including the US.
Vesper Medical is committed to developing safe, efficacious and easy-to-use products for patients with deep venous disease and the physicians who treat them.